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Abstract: Using nanoparticles to deliver chemotherapeutics offers new opportunities for cancer 
therapy, but challenges still remain when they are used for the delivery of multiple drugs, 
especially for the synchronous delivery of hydrophilic and hydrophobic drugs in combination 
therapies. In this paper, we developed an approach to deliver hydrophilic–hydrophobic anticancer 
drug pairs by employing magnetic mesoporous silica nanoparticles (MMSNs). We prepared 
50 nm-sized MMSNs with uniform pore size and evaluated their capability for the loading of 
two combinations of chemotherapeutics, namely doxorubicin–paclitaxel and doxorubicin– 
rapamycin, by means of sequential adsorption from the aqueous solution of doxorubicin and 
nonaqueous solutions of paclitaxel or rapamycin. Experimental results showed that the present 
strategy successfully realized the co-loading of hydrophilic and hydrophobic drugs with 
  high-loading content and widely tunable ratio range. We elaborate on the theory behind the 
molecular interaction between the silica hydroxyl groups and drug molecules, which underlie 
the controllable loading, and the subsequent release of the drug pairs. Then we demonstrate that 
the multidrug-loaded MMSNs could be easily internalized by A549 human pulmonary adeno-
carcinoma cells, and produce enhanced tumor cell apoptosis and growth inhibition as compared 
to single-drug loaded MMSNs. Our study thus realized simultaneous and dose-tunable delivery 
of hydrophilic and hydrophobic drugs, which were endowed with improved anticancer efficacy. 
This strategy could be readily extended to other chemotherapeutic combinations and might have 
clinically translatable significance.
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Introduction
The integration of drug delivery with nanotechnology in the field of cancer therapy 
has attracted much attention in recent decades.1–5 By improving drug bioaccessibility 
and chemosensitivity, nanoparticles as drug-delivery systems (DDSs) could increase 
therapeutic efficacy and mitigate side effects.6,7 Among the recent breakthroughs that 
brought new exciting possibilities to this area, mesoporous silica nanoparticles (MSNs) 
have been highlighted and shown to be a promising candidate for a cancer cell-specific 
delivery vehicle.8–11 These silica-based nanoparticles possess a large number of mes-
oporous channels which endow them with unique structural features including uniform 
and tunable pore size (2–15 nm), high surface area (over 700 m2/g), large pore volume 
(ranges from 0.6–1 cm3/g) and readily functionalized surface.12 In vitro and in vivo 
studies demonstrated that MSNs possessed excellent biocompatibility, and could be 
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degraded and metabolized in a relatively short term (over 
90% were degraded within 96 hours).13,14 These features make 
it possible to reach high drug-loading capacity and allow for 
applying a smaller dose of nanoparticles to minimize particle-
induced toxicity. Furthermore, the controlled release of the 
loaded therapeutic cargoes from MSNs can be easily achieved 
by either a diffusion-dependent process or a stimulus respon-
sive device at the pore openings.15,16 Additionally, the mes-
opores could also protect bioactive drugs from undesired 
enzymatic degradation before reaching the target, owing to 
the inaccessibility of the inner surface to the enzyme in blood 
or tissue plasma.17 Consequently, a variety of cancer thera-
peutic agents have been successfully delivered by MSNs, 
such as chemotherapeutics,18,19 small interfering RNAs 
(siRNAs)20,21 and proteins.22
Since cancer is a complex disease that arises with the 
involvement of multiple factors in multiple steps, the design 
of a treatment will need to address these concerns, such as 
targeting the so-called hallmark features of cancers.23 By 
targeting the key node or pathway essential for cancer cell 
survival or resistance to treatment, we might be able to sup-
press or eradicate cancers more efficiently. In this regard, 
delivering multiple drugs instead of a single therapeutic agent 
is supposed to achieve more significant cancer inhibition.24–26 
For example, Olive and colleagues combined gemcitabine 
with IPI-926 (a Hedgehog signaling pathway inhibitor that 
depletes tumor-associated stromal tissue) produced an 
increased anticancer activity in a pancreatic ductal adeno-
carcinoma mouse model.27 In a clinical trial, patients with 
metastatic renal cell carcinoma had benefited from the com-
bination of bevacizumab (a vascular endothelial growth 
factor inhibitor) and everolimus (a mammalian target of 
rapamycin [mTOR] inhibitor).28 In addition, other strategies 
that combine chemotherapeutics with the inhibition of the 
multidrug resistance (MDR) or antiapoptosis genes can also 
yield improved efficacy, as illustrated by recent studies where 
MSN-based DDSs were used to deliver siRNAs that specifically 
suppressed the MDR pump activity or apoptosis resistance and 
an anticancer drug simultaneously into cancer cells.29,30
Based on the aforementioned advantages, the use of 
MSNs as multidrug DDSs was regarded to improve the 
therapeutic index and reduce side effects.31,32 Despite this, 
the employment of MSNs for combination cancer therapy 
still meets some critical challenges. Firstly, the properties of 
different drugs (eg, solubility, molecular weight) vary greatly, 
which would handicap the drug-loading process. Secondly, 
it is hard to control the amount of different drugs to be loaded 
on nanoparticles to achieve a desirable ratio, which is 
important for improving the clinical effect. Notably, He and 
colleagues have recently demonstrated that drugs/surfactant 
micelles-co-loaded MSNs (drugs-micelles-MMSNs) could 
serve as a new type of multidrug delivery system where 
surfactant micelles (CTAB) was used as chemosensitizer and 
pH-responsive device for the drug doxorubicin (DOX).33 
Their approach offers a new strategy to co-load hydrophobic 
therapeutics in MSNs that induced cancer cell apoptosis 
synergistically. Due to this unique in-situ preparation 
technology, however, the surfactant CTAB could not be 
substituted by chemotherapeutics and the loaded cargo is 
limited to one anticancer drug, thus limiting the application 
extension of multidrug co-delivery. To the best of our 
knowledge, very few studies have been reported about the 
co-delivery of drugs with different molecular properties by 
surfactant-free MSNs. The main reason could be attributed 
to the difficulty in realization and control of co-loading in 
the mesoporous channels. Polymer nanoparticles and 
liposomes have also been used for delivery of hydrophobic 
and hydrophilic anticancer drugs;34 however, chemical 
conjugation was generally involved in the loading processes, 
therefore increasing the operational complexity. Meanwhile, 
the stoichiometry issue is another obstacle to control the dose 
ratio.
In this work, we developed another strategy of co-loading 
water soluble and poorly-soluble chemotherapeutics in 
mesoporous nanoparticles, which was based on our recent 
established magnetic MSN (MMSN) platform.35,36 We herein 
chose DOX, paclitaxel (PTX), and rapamycin (RAPA) as 
model drugs, all of which are currently anticancer drugs used 
in clinical practice and have typical characters of solubility. 
By taking advantages of the mesoporous properties of MMSNs 
and a sequential adsorption of the drugs from their aqueous 
and nonaqueous solutions, the DOX-PTX and DOX-RAPA 
combinations shows high loading capacities on MMSNs, as 
well as an interactive adsorption behavior where the adsorption 
of DOX is affected by that of PTX/RAPA (Figure 1). The 
possibility of tuning the dose ratio of loading drugs to a desir-
able value had been explored. Furthermore, the cellular uptake 
of the drug-loaded MMSNs prepared by this approach, namely, 
DOX-RAPA-MMSNs and DOX-PTX-MMSNs, and the result-
ing cancer cell suppression had also been evaluated.
Material and methods
Materials
Cetyltrimethylammonium bromide (CTAB), 3-aminopropy-
ltri-ethoxysilane (APTES), tetraethylorthosilicate (TEOS), 
and ammonium nitrate (NH4 NO3), these used reagents were 
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analytical reagent grade; fluorescein isothiocyanate isomer 
I (FITC $ 98%). Deionized water was used.
Synthesis of MMSNs
MMSNs were synthesized based on our procedure published 
previously.36 Briefly, magnetic nanoparticles were synthe-
sized by a coprecipitation approach with a ratio of 0.6 mg in 
1 mL chloroform, stabilized by oleic acid, and then dispersed 
in 0.74 mL chloroform, followed by addition of 5 mL aque-
ous solution containing 0.15 g CTAB. After vigorously 
stirring, homogeneous oil-in-water microemulsion was 
obtained, which was then stirred at 70°C for 10 minutes to 
remove the remaining chloroform via evaporation.37 The 
water-dispersed nanoparticles were obtained. Meanwhile, 
FITC and APTES were reacted in 0.5 mL ethanol under dark 
conditions for 2 hours to form FITC-APTES, at molar ratio 
of FITC:APTES = 1:10. The resulted nanoparticles in aque-
ous solution was diluted within 45 mL deionized water, 
succeeded by adding 0.3 mL NaOH solution (2 M), 0.5 mL 
TEOS, 0.5 mL of FITC-APTES solution, and 3 mL ethyl 
acetate sequentially. The mixture was stirred at 600 rpm for 
3 hours at 70°C. The resultant was collected by centrifugation 
and washed with water and ethanol five times. Finally, CTAB 
was removed by refluxing in an ethanol solution of ammo-
nium nitrate (NH4NO3, 10 mg/mL) for 1 hour, and repeated 
three times to yield FITC-labeled MMSNs.
Characterization of MMSNs
Transmission electron microscope (TEM) images were 
obtained by a JEM 2010 instrument (JEOL, Tokyo, Japan) 
with 200 KV acceleration voltage in order to investigate the 
size, morphology, and integrity of the nanoparticles. The 
hydrodynamic size of the samples was measured using 
dynamic light-scattering (DLS) techniques by a Zetasizer Nano 
instrument (Malvern Instruments, Malvern, UK) at 298 K. 
Nitrogen sorption isotherms were measured at 77 K with a 
Micromeritics ASAP 2010 analyzer (Micromeritics, 
Norcross, GA). The specific surface area was calculated by 
the Brunauer-Emmett-Teller (BET) method38 in a linear relative 
pressure (P/P0) range between 0.05 and 0.25. The pore size 
distributions were derived from the desorption branches of the 
isotherms by the nonlocal density functional theory method39 
using the Quantachrome Autosorb software (  version 1.0; 
(Quantachrome Instruments, Boynton Beach, FL). The total 
pore volume (Vp) of the samples was derived by a single point 
measurement of adsorbed nitrogen amount at a relative pressure 
(P/P0) of 0.8 in order to exclude data from the range of inter-
particle spaces. Fluorescence spectrum of sample in water was 
detected using a LS 55 fluorescence spectrometer (Perkin 
Elmer, Waltham, MA) with a xenon lamp.
Drug loading
For loading of DOX, 10 mg of MMSNs was dispersed in 
2 mL of water/methanol (60:40, v:v) mixed solution of DOX, 
and the mixture was shaken at 25°C for 24 hours. The disper-
sion was centrifuged at 10,000 g to collect the DOX-loaded 
MMSNs (DOX-MMSNs), and subsequently the drug-loaded 
MMSNs were washed by distilled water to remove the DOX 
adsorbed on the exterior surface. The remaining solvent was 
removed from MMSNs by vacuum drying at 25°C for at least 
8 hours. The previous adsorption supernatant and wash eluent 
were combined to determine the amount of DOX loaded into 
MMSNs. For PTX- and RAPA-loading, empty and DOX-
loaded MMSNs were suspended in 10 mL PTX or RAPA 
solution in tetrachloromethane, and the mixtures were shaken 
at 25°C for 24 hours. After that, the drug-loaded MMSNs 
were separated by centrifugation and the remaining solvent 
was removed by vacuum drying. Thereafter, drug-loaded 
MMSNs, ie, DOX-MMSNs, PTX-MMSNs, DOX-PTX-
MMSNs and DOX-RAPA-MMSNs were prepared.
Drug-releasing studies
Drug-loaded nanoparticles were dispersed in 2 mL of 
phosphate-buffered saline (PBS), and the dispersion was 
loaded in a dialysis bag with a molecular weight cutoff of 
8000 Dalton. The dialysis bag was then kept in 8 mL PBS 
and gently shaken at 37°C. At different time intervals, 
1 mL of the dialysate was taken out to test the amount of 
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Figure 1 The representative scheme of loading multidrugs in MMSNs. The multidrug- 
loaded MMSNs were prepared by a sequential adsorption procedure, and induced 
synergistic  cancer  cell  suppression.  DOX  adsorb  on  MMSNs  via  electrostatic 
attraction, while PTX and RAPA through hydrogen bond or polar interactions. The 
adsorption of drugs was affected by each other.
Abbreviations: DOX, doxorubicin; MMSNs, magnetic mesoporous silica nanoparticles; 
PTX, paclitaxel; RAPA, rapamycin.
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released drugs. Fresh PBS was added to the dialysate to 
remain the constant volume.
Determination of drug concentration
DOX and RAPA concentrations were determined via analyz-
ing the UV-Vis at 480 nm and 280 nm on a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Rochester, NY), 
respectively.
The PTX concentration was measured on an Agilent 1100 
Series high-pressure liquid chromotograph (Agilent 
  Technologies, Santa Clara, CA) equipped with a C18 reverse 
phase column (Cosmosil C18 AR-II; Nacalai, Tokyo, Japan). 
The analysis was taken at flowing rate of 1 mL/min by using 
65% of methanol/water solution (v/v) as mobile phase, and 
PTX was determined at 227 nm of UV-Vis adsorption 
wavelength.
Cell culture
Human pulmonary adenocarcinoma cells (A549) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal bovine serum, 100 µg/mL 
penicillin, and streptomycin in 37°C humidity atmosphere 
contains 5% CO2. The culture medium was changed every 
2 days before experimental operation.
Cellular uptake of MMSNs
Cells were seeded on cover slips placed in a six-well plate, 
and incubated in 37°C incubator. Twenty-four hours later, 
cells were treated by MMSNs. After culture in 37°C humidity 
incubator, cells were washed with PBS thoroughly, fixed by 
4% paraformaldehyde for 15 minutes, and then treated by 
4′,6-diamidino-2-phenylindole (DAPI) solution for nuclear 
staining. These cover slips were sealed and performed on a 
Leica confocal microscopy system (TCS SP5; Leica, 
  Mannheim, Germany).
Apoptosis assay
Cell apoptosis was determined by fluorescence-activated cell 
sorting (FACS) with an Annexin V apoptosis detection kit 
(SouthernBiotech, Birmingham, AL). A549 cells were seeded 
on six-well plate at 1 × 106 per well, and exposed to DMEM 
medium containing 50 µg/mL empty or drug-loaded MMSNs 
for 24 hours. Cells were then washed by PBS and harvested 
by trypsinization. After being labeled by Annexin V-PE and 
7AAD according to the manufacturer’s protocol, cells were 
immediately analyzed using a flow cytometer (FACSAria II; 
BD Biosciences, San Jose, CA).
Cell proliferation and survival
A549 cells were cultured in a 96-well plate with 5,000 cells/
well. Twenty-four hours later, the culture medium was changed 
with drug-loaded MMSNs. After 48 hours of exposure, a cell-
counting kit-8 (CCK-8) (Sigma Aldrich, St Louis, MO) was 
used to measure the cell viability according to the manufac-
turer’s protocol. The optical absorption of each well at 450 nm 
was read by a microplate reader (BioTek, Seattle, WA).
Statistical analysis
Each experiment was carried out in triplicate at least. Data 
are presented as means ± standard deviation. Differences 
between mean values of two groups and more than two 
groups were tested for significance by Student’s t-test. 
P # 0.05 was considered significant.
Results and discussion
Synthesis and characterization of MMSNs
MMSNs were synthesized by the base-catalyzed and liquid 
phase-seeded growth approach using a CTAB-terminated 
Fe3O4 nanocrystal as the seed to edify the mesoporous shell. 
As shown in the typical TEM image of the MMSNs 
(  Figure 2A), the obtained material is composed of monodis-
persed nanospheres ∼50 nm in size. The MMSN contains a 
single Fe3O4 nanocrystal core wrapped evenly by the mes-
oporous shell and the radially aligned mesopores are clearly 
observed in the shell. The observed pore structure is sup-
ported by nitrogen adsorption/desorption isotherm as shown 
in Figure 2B. The isotherm is of type IV according to the 
International Union of Pure and Applied Chemistry classi-
fication, which is typical for a mesoporous material. There 
are two capillary condensation steps at P/P0 ≈ 0.3–0.4 and 
P/P0 ≈ 0.9, which correspond to the mesopores and textual 
porosity produced by interparticle packing. The primary pore 
size determined from the pore size distribution curve 
(  Figure 2B, inset) is 3.8 ± 1.2 nm, and the surface area and 
the pore volume of MMSNs are determined to be 700 m2/g 
and 0.44 cm3/g, respectively, thus making it possible for 
efficient loading of sufficient amount of anticancer drugs. In 
addition, the hydrodynamic diameter distribution of MMSNs 
exhibits a value of 80 ± 30 nm (Figure 2C). Due to such a 
small particle size, it is possible for MMSNs to leak from 
vasculature into tumor via the so-called enhanced permeabil-
ity and retention effect,40 thus facilitating in vivo applications. 
The photoluminescence excitation and emission spectra 
demonstrated the typical feature of FITC (Figure 2D), indica-
tive of successful incorporation of FITC in the mesoporous 
silica matrix. To sum up, the present synthesis technology 
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generated fluorescent dye-labeled MMSNs. The magnetic 
core imparts the MMSNs with magnetic property for mag-
netic resonance imaging and/or magnetic field manipulation 
in the further biological applications, whereas the fluorescent 
dye makes it convenient to track the particles and investigate 
cellular uptake.
Chemotherapeutics co-loading strategy
We chose three model drugs to explore the ability of MMSNs 
for synchronously loading hydrophobic and hydrophilic 
chemotherapeutic. DOX was chosen as the hydrophilic model 
drug, as it is broadly used for first-line chemotherapy. 
Besides, DOX emit fluorescence when excited at 480 nm 
wavelength, which could facilitate our following study. PTX, 
as a hydrophobic drug, is a routine anticancer agent broadly 
used in clinical treatment. RAPA, another hydrophobic drug, 
was also chosen as a model drug in our study. RAPA was 
initially used as an immunosuppressive agent, but was 
recently identified to possess an antiproliferative effect, and 
its cancer inhibition efficiency was revealed in clinical trials.41 
DOX was combined with PTX or RAPA to form hydrophilic–
hydrophobic pairs.
DOX has a large solubility in aqueous conditions while 
being almost dissoluble in dichloromethane or tet-
rachloromethane. In contrast, PTX and RAPA have poor 
solubility in aqueous liquids. Therefore, the different dis-
solving rates led us to employ a sequential-loading approach. 
Adsorption isotherms for DOX, RAPA, and PTX to MMSNs, 
determined at 298 K individually, are shown in Figure 3. All 
the individual isotherms in Figure 3A imply a typical mono-
layer adsorption behavior: followed by the initial increase, 
the adsorbed amount of drugs reached a plateau at higher 
equilibrium concentrations. The drastic increase of adsorbed 
drug amount at low concentrations indicates a high affinity 
characteristic for the adsorption in all cases. The maximum 
adsorbed amounts from the plateau values are 242.6 ± 4.4, 
185.7 ± 1.6, and 156.0 ± 3.3 µg/mg, or surface excess values 
(defined as the amount of drug adsorbed per unit specific 
surface area of MMSNs) of 0.65, 0.30, and 0.26 µmol/m2 for 
DOX, RAPA, and PTX, respectively. As expected, the loading 
capacities of MMSNs are much higher than other nanoparticle-
based delivery systems resulting from their high surface area 
and large pore volume.12
The co-loading of both the hydrophilic drug (DOX) and 
the hydrophobic drug (RAPA or PTX) in MMSNs was 
implemented via a sequential adsorption procedure, namely, 
loading DOX in aqueous solution first, followed by adsorbing 
RAPA (or PTX) from the nonaqueous medium. Owing to the 
large polarity discrepancy between the organic solvent (tet-
rachloromethane) and DOX, no leakage of DOX was detected 
in the loading process of RAPA or PTX, which makes the 
co-loading possible and efficient. To leave the active binding 
sites available for the adsorption of the hydrophobic drugs, 
the loading degree of DOX was controlled by varying the 
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initial concentrations below the saturation   adsorption condi-
tion. The loading-degree dependence between the hydropho-
bic drug and DOX is shown in   Figure 3B (see also 
Supplementary material, Table S1 and S2). As shown, with 
the increase of the preloaded DOX amount from 0 to 245 µg/
mg, the RAPA-loading degree decreases from its saturation 
adsorption value of 185 µg/mg to 64 µg/mg, while the PTX-
loading degree decreases from 156 µg/mg to 40 µg/mg. In 
other words, when the loading of hydrophobic drugs become 
saturated following the initial DOX loading, the ratio of 
loaded DOX vs RAPA ranges from 0:185 to 245:64 (m:m), 
whereas the ratio of loaded DOX vs PTX ranges from 0:156 
to 245:40 (m:m), with the overall quantity of drugs no less 
than ∼200 µg/mg across the full spectrum of combinations. 
However, the loading of hydrophobic drugs can be reduced 
when their adsorption is not saturated (the area below the 
curves). Taken together, by controlling the starting drug 
concentration in the two   solvents, it is possible to achieve 
any desirable ratios of hydrophilic to hydrophobic drugs.
Regarding the above results, a conclusion can be 
drawn that the present strategy successfully realized the 
co-loading of hydrophilic and hydrophobic drug with high 
loading amounts and widely tunable ratio range. The 
co-loading strategy can thus pave a new way for the applica-
tion of MMSNs in multidrug co-loading; meanwhile, it can 
also be generalized to the loading of other chemotherapeu-
tic combinations composed by drugs with different molec-
ular properties (ie, water solubility).
The above co-loading capability can be rationalized from 
the distinct adsorption interactions between drugs and dif-
ferent binding sites in mesoporous silica under the selected 
solvent conditions (Figure 3C);11 The drug molecules have 
limited number of binding sites for MMSNs (Supplementary 
material, Figure S1); while the accessible adsorption sites 
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on both the inner and the outer pore surface of MCM-41 type 
mesoporous silica materials are composed of Q2 silanols 
([SiO]2Si[OH]2, with a pKa value around 8.5) and Q3 silanols 
([SiO]3SiOH, pKa = 2) with different concentration propor-
tions.42,43 The hydrophilic drug DOX has a pKa of 8.3 and 
thus is positively charged in the aqueous medium, while 
MMSNs are negatively charged (the zeta potential is −31 mV 
at pH = 7), thus leading to a strong electrostatic attraction to 
the negatively charged silanols (deprotoned Q3 silanols). For 
the loading of the hydrophobic drugs in nonaqueous medium, 
electrostatic interaction is negligible; however, hydrogen 
bonds or polar interactions are sufficient to provide consider-
able attraction of the hydrophobic drugs with polar groups 
to the active sites on the silica surface (both Q2 and Q3 
silanols). For this reason, postloading of a hydrophobic drug 
can still take place in the presence of preloaded DOX. 
  Moreover, it is noteworthy to mention again that the loading 
degrees of the hydrophobic drugs all declined with the 
increase of preloaded DOX. When the hydrophobic drugs 
diffused into the mesopore channels, they encounter steric 
hindrance from the already adsorbed DOX on the surface. 
At low DOX coverage, the hydrophobic molecules can more 
or less easily diffuse and transport in the pore channels to 
find available space (not already occupied by the adsorbed 
DOX molecules). As the drug coverage increases, the free 
surface reduces and it becomes increasingly difficult for these 
molecules to diffuse through the pore channels and adsorb 
onto accessible binding sites.
Characterization of DOX release from 
MMSNs in vitro
We next explored the release profiles of DOX-loaded 
MMSNs. Regarding the release properties of PTX and RAPA, 
because of their poor solubility in aqueous solution, the 
released amounts were minimal during the processing period 
of the in vitro experiments (less than 24 hours).18,44 So we 
then only investigated the in vitro release behavior of DOX 
in the co-loading system with the same loading degree of 
DOX (∼100 µg/mg), which might help us to understand the 
intracellular performance for the dual-drug coloaded 
MMSNs. The cumulative DOX release curves of DOX-
MMSNs, DOX-RAPA-MMSNs, and DOX-PTX-MMSNs 
systems in PBS at 37°C are shown in Figure 4. Initially, for 
approximately the first 6 hours, a rapid release of DOX could 
be observed in all systems. Subsequently, a stage of slow 
release followed up to the cumulative release time of 
48 hours. For DOX-MMSNs, the DOX release amount 
reached 26% at 10 hours, whereas 23% and 19% of the DOX 
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Figure 4 The release profiles of DOX on different loading fashions. DOX from 
individual  (■),  DOX-PTX  co-loading  (●),  and  DOX-RAPA  co-loading  (∆).  The 
releasing experiment was carried out in PBS at 310 K. The cumulative release of 
DOX is about 25% in the three different situations, but the release of DOX from the 
individual loading system is faster than that from the co-loaded fashion.
Abbreviations: DOX, doxorubicin; PTX, paclitaxel; RAPA, rapamycin.
was released at the same time point in the case of DOX-PTX-
MMSNs and DOX-RAPA-MMSNs. Moreover, it took 
24 hours for the amount of DOX release from DOX-RAPA-
MMSNs to reach as high as 24%. This means that dual-
delivery  systems  of  DOX-RAPA-MMSNs  and 
DOX-PTX-MMSNs displayed a slower release rate than that 
of DOX-MMSNs.
The Korsmeyer–Peppas model (Eq. 1) is a comprehen-
sive equation to describe and explain the kinetics of drug 
release from the matrices.45,46 This diffusion model is 
expected to be valid up to approximately 60% of cumulative 
drug released; therefore, the data for analysis were restricted 
to that range.
 
M
M
k
t n t
∞
=
 
(1)
where Mt and M∞ denote the cumulative mass of drug released 
at time t and at infinite time, respectively; k is a kinetic con-
stant characteristic of the drug–carrier system; and n is an 
exponent that characterizes the mechanism of drug release.
Our results indicated that the data points up to 60% of 
the drug release in the cumulative release curve of the co-
loading system were fitted in the Korsmeyer–Peppas model 
with good linearity and the exponent n in every case was 
lower than 0.45. According to the Korsmeyer–Peppas model, 
the drug release is a simple diffusion-controlled Fickian 
process for our co-delivery system, which involves two 
processes: first, the solvent diffuses into the pores of the 
mesoporous silica to dissolve the drug and second, the dis-
solved drug molecules diffuse out of the pore.47 It has been 
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reported previously that a large loading amount of 
hydrophobic drug48 or modifying the pore opening with a 
hydrophobic group after drug loading49 makes the pore sur-
face or pore opening more hydrophobic, which could restrict 
the kinetics of water diffusion into the matrix and slow down 
the release process subsequently. In our co-delivery system, 
the sustained release of DOX can thus be well explained in 
the case of the samples with postloaded RAPA or PTX.
Uptake of MMSNs and release  
of loaded drugs in cancer cells
With the establishment of multidrug-loading and release 
profile for MMSNs, we then tested whether these particles 
could be readily internalized by cancer cells followed by 
release of the cargoes. For this purpose, MMSNs were labeled 
with FITC, and exposed to A549 cancer cells (adenocarcino-
mic human alveolar basal epithelial cells) for 1 hour. The 
result from confocal microscopy observation demonstrated 
that all cells rendered strong green fluorescence which 
dispersed in cytoplasm surrounding the nuclei, implying that 
MMSNs were successfully internalized by A549 cells (Sup-
plementary material, Figure S2). By taking the advantage of 
fluorescent spectral properties of DOX (it emits fluorescence 
ranging from 545 nm to 590 nm when excited at about 480 nm 
wavelength), the DOX release from MMSNs to the cells can 
be conveniently observed. Single- or multidrug-loaded 
MMSNs were incubated with A549 cells for 2 hours followed 
by fluorescence microscopy observation (Figure 5). At this 
time point, the MMSNs had readily been taken up by cancer 
cells based on the previous results (Supplementary material, 
  Figure S2). In fact, a time course analysis of MMSNs uptake 
by A549 cells indicated that internalization process occurred 
in as short as 15 minutes at 37°C, while drug release occurred 
in 30 minutes (Supplementary material, Figure S3).
A
DOX FITC Merge
B
C
Figure 5 Intracellular distribution and drug release of drug-loaded MMSNs. A549 cells were treated by drug-loaded MMSNs for 2 hours, and then fixed and observed 
by confocal microscope. Both individual (A) and PTX (B) or RAPA (C) co-loaded DOX were successfully released from MMSNs, as the red fluorescence distributed in 
the nucleus.
Note: Scale bar: 50 µm.
Abbreviations: DOX, doxorubicin; MMSNs, magnetic mesoporous silica nanoparticles; PTX, paclitaxel; RAPA, rapamycin.
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The red fluorescence indicative of DOX was clearly 
observed inside all cells, with focused distribution in the 
nuclear region and scattered distribution in the cytoplasm. 
This is because DOX easily permeates the nuclear envelope 
and intercalates DNA.50 The green fluorescence was detected 
in the cell plasma but also in the nuclear zone. This 
contradictive phenomenon of distribution of MMSNs inside 
the cells could be explained by the fact that DOX also emits 
green fluorescence when excited at 480 nm wavelength, which 
overlaps with the spectrum of FITC (Supplementary material, 
Figure S4). It is reported that MMSNs with size ranging from 
50 to 200 nm were generally internalized and transported into 
lysosomes.51 Exactly how the particles get internalized and 
transported in the cells and how the drugs get unloaded and 
permeate the intracellular membranous structures will require 
further investigation. Nonetheless, for all the three systems, 
drug-loaded MMSNs were successfully internalized by cancer 
cells and the loaded drugs could be released.
Improved cancer cell killing and inhibition 
by the multidrug-loaded MMSNs
Thereafter, we tested the induced effects of single- and mul-
tidrug-loaded MMSNs in the induction of cancer cell death 
and inhibition of growth. To keep a commensurable inhibitory 
effect, the loaded amount of DOX in MMSNs was controlled 
to be approximately 90 µg/mg, which was chosen based on 
the half maximal inhibitory concentration (IC50) of free drug 
in A549 cells in our pilot experiment (data not shown) and 
published studies.52 The ratio of DOX to PTX was scaled to 
9:1 (m:m) by adopting our sequential and tunable loading 
strategy. Similarly, for the DOX-RAPA combination, the ratio 
was set to be 1:1 (m:m). We determined the percentage of 
cells undergoing apoptosis by flow cytometry after treatment 
with different drug-loaded MMSNS. Empty MMSNs without 
loading any drugs were included as controls. Up to 50 µg/mL, 
empty MMSNs posed limited toxicity to A549 cells after 24 
or 48 hours of incubation (Figures 6 and 7).
A549 cells were exposed to empty or drug-loaded 
MMSNs at 50 µg/mL for 24 hours, and stained with Annexin 
V-PE/7AAD, followed by flow cytometric analysis. Empty 
MMSNs only induced almost negligible apoptosis (2.74% 
of total cells) (Figure 7), which suggests good   biocompatibility. 
In contrast, single-drug-loaded MMSNs induced consider-
able apoptosis, which was 14.65% (DOX-MMSNs), 7.64% 
(PTX-MMSNs) and 8.28% (RAPA-MMSNs) of total cells, 
respectively. Meanwhile, the apoptotic ratios in cells 
treated by multidrug-loaded MMSNs were 30.72% for 
DOX-PTX-MMSNs and 47.30% for DOX-RAPA-MMSNs, 
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Figure 6 Apoptosis assay of A549 cells induced by single- or multidrug-loaded 
MMSNs.  A549  cells  were  treated  by  50  µg/mL  empty  nanoparticles  (MMSNs), 
DOX-MMSNs, PTX-MMSNs, and DOX–PTX-MMSNs for 24 hours. The harvested 
cells were stained by Annexin V-PE/7AAD apoptosis kit, and the flow cytometry 
showed DOX–PTX-MMSNs induced more notable apoptotic effects than DOX-
MMSNs and PTX-MMSNs. Empty MMSNs produced a negligible effect. Grey curve 
represents the apoptosis of untreated cells.
Abbreviations:  DOX,  doxorubicin;  MMSNs,  magnetic  mesoporous  silica 
nanoparticles; PTX, paclitaxel; RAPA, rapamycin.
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Figure 7 Tumor cell growth inhibitions induced by drug-loaded MMSNs. A549 cells 
were  treated  with  empty  or  drug-loaded  MMSNs  for  48  hours.  Notable  cell 
growth suppressions were observed at: (A) 5 µg/mL of DOX–PTX-MMSNs and 
(B) 5–50 µg/mL of DOX–RAPA-MMSNs (P # 0.05).
Abbreviations:  DOX,  doxorubicin;  MMSNs,  magnetic  mesoporous  silica 
nanoparticles; PTX, paclitaxel; RAPA, rapamycin.
which were greater than the arithmetic sum of the apoptotic 
ratios induced by each single-drug-loaded MMSNs. This 
result implied that the combined delivery of multidrugs 
produced enhanced cell apoptosis.
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Furthermore, we tested the growth inhibition and toxicity 
effect of drug-loaded MMSNs on tumor cells in addition to 
the flow cytometry-based apoptosis assay. A549 cells were 
treated by drug-loaded MMSNs for 48 hours followed by cell 
viability analysis via using a CCK-8 cell counting kit 
(  Figure 7). Empty MMSNs induced negligible toxic effect at 
low particle concentration, while minute toxicity was detect-
able at 50 µg/mL. This might be attributed to the bare surface 
of the MMSNs used in our experiments, which could be 
eliminated by surface modification in further application.53 
In contrast, both individual and combinative loading groups 
produced dose-dependent tumor cell growth inhibitions. 
Particularly, the inhibition effect of the multidrug-loaded 
MMSNs was more significant than that of single-drug-loaded 
MMSNs. Specifically, in the PTX-DOX combination 
(  Figure 7A), the IC50 were ∼6.8 and 50 µg/mL for DOX-
MMSNs and PTX-MMSNs, and 2.3 µg/mL for DOX-PTX-
MMSNs, respectively; this synergistic effect of growth 
inhibition was most evident at 5 µg/mL of MMSNs 
(P # 0.05). In the RAPA-DOX combination (Figure 7B), the 
IC50 were ∼6.8 and 28.8 µg/mL for DOX-MMSNs and RAPA-
MMSNs versus 2.5 µg/mL for DOX-RAPA-MMSNs; the 
synergistic effect of cell growth inhibition was clearly 
observed from 0.5 to 50 µg/mL of MMSNs (P # 0.05).
Though the loading of two distinct chemotherapeutics 
instead of one chemotherapeutic plus the CTAB chemosensi-
tizer as reported previously,33 our experimental data implied 
a more unambiguous synergistic effect in both cell apoptosis 
and growth inhibition. Additionally, by comparing the drug 
concentrations required to achieve similar levels of cell growth 
inhibition, we found this value for drugs loaded in MMSNs 
was much smaller than that for drugs in the free form 
(Supplementary material, Figure S5). In other words, drug-
loaded MMSNs produced more significant inhibition with the 
same amount of drugs used. Similar effects were also reported 
by Chang and colleagues.44 On the other hand, the DOX-PTX 
combination was reported to have increased antitumor activity 
against solid tumors, eg, lung, colon, breast, and liver 
cancer,52,54 while the use of the RAPA-DOX combination has 
yet to be documented in clinical applications. Herein we 
demonstrated notable synergistic anticancer effects for both 
DOX-PTX and DOX-RAPA combinations. Furthermore, by 
taking advantage of different binding sites in surfactant free 
mesoporous silica under the selected solvent conditions, our 
co-loading strategy was more general compared to He’s work 
which was limited to drug/surfactant combinations.33 By 
combining the use of MMSNs for drug delivery, and choice 
of chemotherapeutics combinations, we have produced a 
feasible DDS with enhanced therapeutic efficacy in cancer 
treatment, which might have translatable significance.
Conclusion
In summary, we developed an approach to co-load hydro-
philic and hydrophobic chemotherapeutics on MSNs, with 
the aim of realizing multidrug delivery for cancer therapy. 
Two types of chemotherapeutics combinations, ie, DOX-
PTX and DOX-RAPA, were successfully loaded into the 
50 nm MSNs. The experimental data indicated that the ratio 
of loaded DOX versus RAPA could be easily tuned from 
0:185 to 245:64 (m:m), while the ratio of loaded DOX 
versus PTX from 0:156 to 245:40 (m:m), with the overall 
quantity of drugs no less than ∼200 µg/mg across the full 
spectrum of combinations. The nanoparticles prepared by 
this co-loading fashion could be internalized efficiently by 
cancer cells, and produced an enhanced cancer cell sup-
pression compared to individual loading. So far, this is the 
first endeavor that employs MSNs to load hydrophilic and 
hydrophobic chemotherapeutics simply by adsorbing drugs 
from different solvents. Our research thus realized hydro-
phobic–hydrophilic drugs loading, amount/ratio control, 
and simultaneous delivery simultaneously. Further work is 
needed to modify the surface of MMSNs with biocompat-
ible polymers concerning their in vivo circulation and 
stabilization; and via choosing an optimal dose ratio to 
evaluate this co-loading fashion and the induced therapeutic 
effect in a tumor model. These data would facilitate multi-
drug combination chemotherapy.
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Table S1 The loading dose ratio of DOX and PTX
DOX (µg/mg) 0.0 45.9 93.3 140.5 186.3 216.2
PTX (µg/mg, mean ± SD) 156.0 ± 3.3 140.1 ± 1.8 120.4 ± 1.0 108.9 ± 0.7 79.8 ± 1.3 39.7 ± 1.3
Abbreviations: DOX, doxorubicin; PTX, paclitaxel; SD, standard deviation.
Table S2 The loading dose ratio of DOX and RAPA
DOX (µg/mg) 0.0 58.3 120.1 179.6 224.1
RAPA (µg/mg, mean ± SD) 180.7 ± 1.6 124.0 ± 2.6 91.8 ± 1.4 70.9 ± 2.1 63.6 ± 1.8
Abbreviations: DOX, doxorubicin; RAPA, rapamycin; SD, standard deviation.
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Figure S1 The three-dimensional molecular structures of doxorubicin, paclitaxel, and rapamycin (constructed by ChemBio 3D, molecular structure based on ChemACX 
database). Only polar hydrogen is shown.
Supplementary information
FITC DAPI Merge
Figure S2 The cellular uptake and distribution of MMSNs on A549 cancer cells. MMSNs were labeled by FITC, and cultured with cells for 1 hour. Confocal microscopy 
image showed MMSNs were located in cytoplasm, and no green fluorescence was observed in nuclei which were stained by DAPI.
Note: Scale bar: 100 µm.
Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate; MMSNs, magnetic mesoporous silica nanoparticles.
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Figure S3 The cellular uptake of DOX-MMSNs and the release of DOX from MMSNs. A549 cells were treated with 50 µg/mL of DOX-MMSNs for 10, 30, 60, and 
180 minutes, and observed by confocal microscopy. The internalization of MMSNs could be detected at the time point of 10 minutes as weak green fluorescence was 
observed. The fluorescence intensity increased accordingly with the prolonging of the treatment time. It was observed that the red fluorescence of DOX was almost 
undetectable until the incubating time increased to 30 min, which indicated that the nanoparticles were internalized but DOX was still kept in MMSNs until the time point 
of 30 minutes.
Note: Scale bar: 100 µm.
Abbreviations: DOX, doxorubicin; FITC, fluorescein isothiocyanate; MMSNs, magnetic mesoporous silica nanoparticles.
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Figure S4 The fluorescence of DOX was detectable in FITC channel. (A) A549 cells were treated with free DOX in PBS at 5 µg/mL for 1 hour, fixed, and prepared for 
confocal microscopy. The fluorescence of DOX was mostly located in nuclei, and detectable in both 510–540 nm (FITC channel) and 560–590 nm emission range. (B) 
A549 cells were treated with empty MMSNs or DOX-MMSNs for 1 hour. Live cells were observed under confocal microscope. DOX-MMSNs-treated cells shows nucleic 
red fluorescent, whereas empty MMSNs-treated cells did not, which implies that it was the loaded DOX rather than MMSNs that entered nuclei.
Note: Scale bar: 50 µm.
Abbreviations: DOX, doxorubicin; FITC, fluorescein isothiocyanate; MMSNs, magnetic mesoporous silica nanoparticles.
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Figure S5 The growth inhibition of A549 cells induced by free or drug-loaded MMSNs with the approximate drug-loading amounts. The DOX-MMSNs loading content was 
90 µg/mg, while the PTX-MMSNs loading content was 10 µg/mg. The cell growth inhibition induced by drugs loaded in MMSNs is more significant compared to that induced 
by free drugs.
Abbreviations: DOX, doxorubicin; MMSNs, magnetic mesoporous silica nanoparticles; PTX, paclitaxel.
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